Pfizer cuts earnings outlook on lower Covid-19 drug sales

Australia News News

Pfizer cuts earnings outlook on lower Covid-19 drug sales
Australia Australia Latest News,Australia Australia Headlines

The US pharmaceutical giant Pfizer sharply scaled back its earnings outlook for the year, blaming lower-than-expected sales of two drugs used to treat Covid-19, the company said Friday. The sharp revision to expected sales of Paxlovid, an oral antiviral drug, and the Covid-19 vaccine Comirnaty sent Pfizer's stock tumbling.

  • 📰 brieflyza
  • ⏱ Reading Time:
  • 8 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 7%
  • Publisher: 68%

The US pharmaceutical giant Pfizer sharply scaled back its earnings outlook for the year, blaming lower-than-expected sales of two drugs used to treatIt now"anticipates full-year 2023 revenues to be in the range of $58.0 to $61.0 billion, versus its previous guidance range of $67.0 to $70.0 billion," Pfizer announced in a statement.

The sharp revision to expected sales of Paxlovid, an oral antiviral drug, and the Covid-19 vaccine Comirnaty sent Pfizer's stock tumbling.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

brieflyza /  🏆 10. in AU
 

Australia Australia Latest News, Australia Australia Headlines



Render Time: 2025-01-14 02:36:25